"It's easy to do something only against Omicron. What is scientifically and technically more challenging ... is to be effective against everything known so far, so you don't have two different vaccines for different variants," Bourla said, speaking at a press conference held by the International Federation of Pharmaceutical Manufacturers & Associations.
